Viz Cardio Suite
Hypertrophic Cardiomyopathy
Key Facts
About Viz.ai
Viz.ai is a pioneering AI-powered care coordination platform company founded in 2016. It has developed a comprehensive suite of FDA-cleared algorithms that auto-detect suspected diseases from medical scans (CT, EKG, echo) and facilitate real-time communication among care teams to accelerate treatment. The company serves both healthcare providers and life sciences partners, with solutions spanning neurovascular, cardiovascular, vascular, trauma, oncology, and radiology. Viz.ai is a private, revenue-generating company positioned at the intersection of AI diagnostics and clinical workflow optimization.
View full company profileAbout Viz.ai
Viz.ai is a pioneering AI-powered care coordination platform company founded in 2016. It has developed a comprehensive suite of FDA-cleared algorithms that auto-detect suspected diseases from medical scans (CT, EKG, echo) and facilitate real-time communication among care teams to accelerate treatment. The company serves both healthcare providers and life sciences partners, with solutions spanning neurovascular, cardiovascular, vascular, trauma, oncology, and radiology. Viz.ai is a private, revenue-generating company positioned at the intersection of AI diagnostics and clinical workflow optimization.
View full company profileAbout Viz.ai
Viz.ai is a pioneering AI-powered care coordination platform company founded in 2016. It has developed a comprehensive suite of FDA-cleared algorithms that auto-detect suspected diseases from medical scans (CT, EKG, echo) and facilitate real-time communication among care teams to accelerate treatment. The company serves both healthcare providers and life sciences partners, with solutions spanning neurovascular, cardiovascular, vascular, trauma, oncology, and radiology. Viz.ai is a private, revenue-generating company positioned at the intersection of AI diagnostics and clinical workflow optimization.
View full company profileOther Hypertrophic Cardiomyopathy Drugs
| Drug | Company | Phase |
|---|---|---|
| Cardiovascular Target Program | Micar Innovation | Discovery |